255 related articles for article (PubMed ID: 15951821)
1. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
2. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
[TBL] [Abstract][Full Text] [Related]
3. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome.
Celebi JT; Ward KM; Wanner M; Polsky D; Kopf AW
Clin Exp Dermatol; 2005 Jan; 30(1):68-70. PubMed ID: 15663508
[TBL] [Abstract][Full Text] [Related]
5. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
[TBL] [Abstract][Full Text] [Related]
6. Pathways to melanoma development: lessons from the mouse.
Walker GJ; Hayward NK
J Invest Dermatol; 2002 Oct; 119(4):783-92. PubMed ID: 12406321
[TBL] [Abstract][Full Text] [Related]
7. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.
Tachibana I; Smith JS; Sato K; Hosek SM; Kimmel DW; Jenkins RB
Am J Med Genet; 2000 May; 92(2):136-41. PubMed ID: 10797439
[TBL] [Abstract][Full Text] [Related]
8. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
9. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao H; Zhang X; Fowlkes K; Haluska FG
Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
[TBL] [Abstract][Full Text] [Related]
10. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
11. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
13. The genetics of cutaneous melanoma.
Pollock PM; Trent JM
Clin Lab Med; 2000 Dec; 20(4):667-90. PubMed ID: 11221509
[TBL] [Abstract][Full Text] [Related]
14. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus.
Hernández L; Beà S; Pinyol M; Ott G; Katzenberger T; Rosenwald A; Bosch F; López-Guillermo A; Delabie J; Colomer D; Montserrat E; Campo E
Cancer Res; 2005 Mar; 65(6):2199-206. PubMed ID: 15781632
[TBL] [Abstract][Full Text] [Related]
15. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
Bachmann IM; Straume O; Akslen LA
Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
[TBL] [Abstract][Full Text] [Related]
17. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.
Zou X; Ray D; Aziyu A; Christov K; Boiko AD; Gudkov AV; Kiyokawa H
Genes Dev; 2002 Nov; 16(22):2923-34. PubMed ID: 12435633
[TBL] [Abstract][Full Text] [Related]
18. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.
Fulci G; Labuhn M; Maier D; Lachat Y; Hausmann O; Hegi ME; Janzer RC; Merlo A; Van Meir EG
Oncogene; 2000 Aug; 19(33):3816-22. PubMed ID: 10949938
[TBL] [Abstract][Full Text] [Related]
19. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
[TBL] [Abstract][Full Text] [Related]
20. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
Tsao H; Goel V; Wu H; Yang G; Haluska FG
J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
